Moleculin Biotech, Inc. (MBRX) is a publicly traded Healthcare sector company. As of July 31, 2026, MBRX trades at $0.98 with a market cap of $9.61M and a P/E ratio of -0.04. MBRX moved -0.98% today. Year to date, MBRX is -71.82%; over the trailing twelve months it is -94.26%. Its 52-week range spans $1.01 to $91.25. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces MBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for MBRX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $0.98 |
| Market Cap | $9.61M |
| P/E Ratio | -0.04 |
| EPS | $-28.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $91.25 |
| 52-Week Low | $1.01 |
| Volume | 1.48M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-33.56M |
| Gross Margin | 0.00% |
2 analysts cover MBRX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.